(Q40739600)

23 September 2017

title

Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1540980

6 October 2022

1 reference

S. H. Lim

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1540980

6 October 2022

A. C. Newland

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1540980

6 October 2022

S. Kelsey

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1540980

6 October 2022

A. Bell

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1540980

6 October 2022

E. Offerman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1540980

6 October 2022

C. Rist

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1540980

6 October 2022

D. Gozzard

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1540980

6 October 2022

D. Bareford

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1540980

6 October 2022

M. P. Smith

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1540980

6 October 2022

A. H. Goldstone

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1540980

6 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1540980

6 October 2022

publication date

1 January 1992

1 reference

Cancer Immunology, Immunotherapy

23 September 2017

published in

1 reference

23 September 2017

volume

34

1 reference

23 September 2017

issue

5

1 reference

23 September 2017

page(s)

337-342

1 reference

Thyroid disorders in 2 cases of acute myeloid leukaemia following treatment with recombinant interleukin-2 infusion

23 September 2017

cites work

1 reference

12 December 2020

Human natural killer cells can inhibit clonogenic growth of fresh leukemic cells

1 reference

12 December 2020

Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias

1 reference

12 December 2020

Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): clinical and biological findings.

1 reference

12 December 2020

Production of tumour-derived suppressor factor in patients with acute myeloid leukaemia

1 reference

12 December 2020

Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy

1 reference

12 December 2020

Interleukin-2 augments natural killer cell activity

1 reference

12 December 2020

Long term culture of tumour-specific cytotoxic T cells

1 reference

12 December 2020

Cellular cytotoxic function and potential in acute myelogenous leukaemia

1 reference

12 December 2020

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

12 December 2020

Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

1 reference

12 December 2020

Recent advances in the understanding of the biochemistry and clinical pharmacology of interleukin-2.

1 reference

12 December 2020

Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

Lymphokine-activated killer (LAK) cells inhibit the clonogenic growth of human leukemic stem cells

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission

1 reference

12 December 2020

THE PLACE OF BONE-MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKÆMIA

1 reference

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

12 December 2020

Cytotoxic effects of tumour necrosis factor and gamma-interferon on acute myeloid leukaemia blasts

1 reference

12 December 2020

Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01741555

1 reference

Dimensions Publication ID

23 September 2017

1023171844

0 references

1 reference